Chimerix (NASDAQ:CMRX) PT Raised to $7.00 at HC Wainwright

Chimerix (NASDAQ:CMRX) had its target price lifted by equities research analysts at HC Wainwright from $5.00 to $7.00 in a research note issued to investors on Thursday, The Fly reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 112.12% from the company’s previous close.

A number of other research firms have also weighed in on CMRX. Zacks Investment Research lowered shares of Chimerix from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Cowen restated a “hold” rating and set a $3.00 price objective on shares of Chimerix in a research note on Thursday, May 9th. Finally, ValuEngine upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Friday, June 28th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Chimerix has an average rating of “Hold” and a consensus target price of $4.00.

Shares of Chimerix stock traded down $0.16 during trading on Thursday, hitting $3.30. The company’s stock had a trading volume of 315,421 shares, compared to its average volume of 398,596. The business’s fifty day moving average price is $3.67. The firm has a market capitalization of $168.53 million, a P/E ratio of -2.31 and a beta of 1.24. Chimerix has a 52 week low of $1.74 and a 52 week high of $4.51.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.35). The company had revenue of $2.36 million during the quarter, compared to analyst estimates of $2.00 million. Chimerix had a negative net margin of 757.77% and a negative return on equity of 36.85%. As a group, equities research analysts predict that Chimerix will post -1.02 EPS for the current fiscal year.

In other news, Director Martha J. Demski acquired 18,000 shares of Chimerix stock in a transaction on Tuesday, May 28th. The stock was acquired at an average cost of $3.60 per share, for a total transaction of $64,800.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Michael A. Sherman acquired 30,000 shares of Chimerix stock in a transaction on Monday, May 20th. The shares were purchased at an average price of $3.48 per share, with a total value of $104,400.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 78,000 shares of company stock valued at $256,800. 9.40% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. HRT Financial LLC purchased a new stake in shares of Chimerix during the 4th quarter valued at about $40,000. SG Americas Securities LLC boosted its holdings in shares of Chimerix by 105.4% during the 1st quarter. SG Americas Securities LLC now owns 20,590 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 10,567 shares during the last quarter. Citigroup Inc. boosted its holdings in shares of Chimerix by 81.2% during the 4th quarter. Citigroup Inc. now owns 19,570 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 8,771 shares during the last quarter. Quantitative Systematic Strategies LLC purchased a new stake in shares of Chimerix during the 2nd quarter valued at about $67,000. Finally, Marshall Wace LLP purchased a new stake in shares of Chimerix during the 1st quarter valued at about $166,000. 69.52% of the stock is currently owned by hedge funds and other institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Further Reading: Why are analyst ratings important in trading stocks?

The Fly

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.